New York, Feb 23, 2026, 05:22 EST — Premarket
- Mangoceuticals shares slipped in premarket action, cooling off after surging the previous session.
- This came right after the company flagged initial momentum for its $99-per-month testosterone therapy program.
- Traders are eyeing the open for signs of continued momentum, plus any new filings after that heavy volume.
Mangoceuticals, Inc. shares slipped roughly 4% to about 51 cents in premarket action Monday, trimming a fraction off Friday’s surge of nearly 49% that pushed the stock to 53 cents.
The drop stands out: Mangoceuticals trades as a thinly priced micro-cap and tends to lurch on even modest headlines. Friday’s action yanked it back into the sights of traders just before the new week.
Friday’s volume exploded to nearly 349 million shares, a sharp jump from just 8 million on Thursday, exchange data from Investing.com show. That kind of spike tends to pull in fast-moving traders—and just as quickly, challenge their resolve.
Shares jumped after Mangoceuticals’ Feb. 19 update flagged “early traction” for its $99-a-month all-inclusive injectable testosterone replacement therapy program. According to the company, since mid-December, sales for the injectable TRT offering climbed 336% month-over-month, while the cost to acquire new customers dropped 54%. CEO Jacob Cohen described the initial demand as “encouraged” and noted Mangoceuticals is working to expand into a wider wellness platform. GlobeNewswire
The company put out that press release via an SEC filing under Regulation FD—a rule designed to prevent selective disclosure by making sure material news reaches every investor simultaneously.
The stock jumped roughly 70% in premarket trading Friday after the announcement, according to Investing.com. The company is banking on TRT as its main engine for growth, with plans to put money into both injectable and oral options—among them PRIME by MangoRx, which uses Kyzatrex.
Friday was volatile. Shares kicked off near 62 cents, swinging from roughly 48 cents up to 69 cents. By the close, the company’s market cap stood at about $9 million, per Moomoo data.
Mangoceuticals pushes men’s and women’s health and wellness products via a telemedicine platform, offering treatments for erectile dysfunction, hair loss, hormone therapy, and weight loss, Reuters’ company profile shows.
Traders are focused on more than just percentage growth; the real test is repeat orders, retention, and if those slimmer marketing costs hold up as the company moves past its earliest users. They’ll be watching for any additional details tying these numbers directly to revenue and cash burn.
Still, the risk is front and center. Mangoceuticals got a warning from Nasdaq after its stock closed under $1 for 30 straight sessions, violating the exchange’s minimum bid rule, according to a filing. The company now faces an Aug. 3, 2026 deadline to fix things by notching at least 10 closes at $1 or above.
